Common stock
- Symbol
- DARE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
DARENASDAQEQUITYCurrent
Item Results 2.02 of Operations and Financial Condition. On November 16, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026, a copy of which is furnished as Exhibit 99.1 to this report.…
We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.
DARE BIOSCIENCE, INC · 8-K · Filed 2026-11-16
Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington, D.C. Commercial launch of Flora Sync LF5™ showing encouraging early indicators, including orders from 27 states, provider office reorder and positive consumer feedback Company surpassed $43 million in cumulative non-dilutive grant funding supporting advancement of DARE-LARC1; exploring potential strategic collaboration opportunities in areas including obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1 medicines, for the underlying DARE-IDDS platform Company to host conference call and webcast today, November 16, 2026, at 4:30 p.m. Eastern Time - Access the webcast here SAN DIEGO, November 16, 2026 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter end…
Open exhibit ↗